Trial Profile

An Investigator initiated trial of SNUG01 patients with ALS

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SNUG 01 (Primary)
Indications Amyotrophic lateral sclerosis
Focus Adverse reactions

Most Recent Events

15 Aug 2025 According to a SineuGene Therapeutics media release, Professor Merit Cudkowicz, Director of the Healey & AMG Center for ALS at Massachusetts General Hospital is the global principal investigator of the trial.
15 Aug 2025 According to a SineuGene Therapeutics media release, National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for SNUG01 for amyotrophic lateral sclerosis (ALS).
26 Jun 2025 According to a SineuGene Therapeutics media release, the FDA cleared the Investigational New Drug (IND) application for SNUG01 in March 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com